REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) announced participation in multiple investor conferences in October–November 2025. The company will join Chardan's 9th Annual Genetic Medicines Conference panels on Oct 21, 2025 at 2:00 PM ET and 2:45 PM ET in New York, a Guggenheim Securities fireside chat on Nov 10, 2025 at 9:00 AM ET in Boston, and a Stifel fireside chat on Nov 11, 2025 at 1:20 PM ET in New York. Live webcasts of select events will be available in the Investors section at www.regenxbio.com, with archived replays available for approximately 30 days after each event.

ROCKVILLE, Md., Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

Chardan's 9th Annual Genetic Medicines Conference
Panel "Battleground States for Muscular Dystrophies": Tuesday, October 21 at 2:00 p.m. ET
Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers": Tuesday, October 21 at 2:45 p.m. ET
Location: New York, NY

Guggenheim Securities 2^nd Annual Healthcare Innovation Conference
Fireside Chat: Monday, November 10, 2025 at 9:00 a.m. ET
Location: Boston, MA

Stifel 2025 Healthcare Conference
Fireside Chat: Tuesday, November 11, 2025 at 1:20 p.m. ET 
Location: New York, NY

Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302584430.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO (RGNX) present at Chardan's Genetic Medicines Conference in 2025?

REGENXBIO will participate on Oct 21, 2025 with panels at 2:00 PM ET and 2:45 PM ET in New York.

How can investors watch REGENXBIO (RGNX) presentations on Oct–Nov 2025?

Live webcasts of select events will be on the Investors section of www.regenxbio.com, with archived replays for about 30 days.

What time is REGENXBIO's Guggenheim fireside chat (RGNX) on Nov 10, 2025?

The Guggenheim fireside chat is scheduled for Nov 10, 2025 at 9:00 AM ET in Boston.

When is REGENXBIO's (RGNX) Stifel 2025 Healthcare Conference appearance?

REGENXBIO will appear at Stifel on Nov 11, 2025 at 1:20 PM ET in New York.

Will REGENXBIO (RGNX) provide archived webcasts after the 2025 conferences?

Yes. Archived replays will be available for approximately 30 days after the events on the company's investor website.

Which topics will REGENXBIO (RGNX) cover at Chardan's Oct 21, 2025 panels?

REGENXBIO is scheduled for panels titled "Battleground States for Muscular Dystrophies" and "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers".